NCT04448886: Sacituzumab Govitecan Vs Pembrolizumab In HR+ / HER2 – MBC

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated symptomatic brain metastases – see trial for details; Patients who have received more than 1 prior chemotherapeutic regimen for metastatic breast cancer; Patients with prior therapy of irinotecan, sacituzumab govitecan, or an anti-PD-1, anti- PD-L1/L2 therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)

Comments are closed.

Up ↑